EUVIMEDEUVIMED entdecken
Open Access

The Clinical Impact of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) in Gastric Cancer Patients Who Receive Curative Treatment

Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Sosuke Yamamoto, Mamoru Uchiyama, Koji Numata, Keisuke Kazama, Ayako Tamagawa, Aya Saito, Norio Yukawa

In Vivo · 2024

DOI: 10.21873/invivo.13720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Toru Aoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yokohama City University, Yokohama, Japan t-aoyama@lilac.plala.or.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Hemoglobins, Blood Platelets, Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: We hypothesized that the hemoglobin, albumin, lymphocyte, and platelet (HALP) score may be a promising marker for the treatment and management of gastric cancer (GC). To test this hypothesis, we evaluated the clinical impact of the HALP score in patients with GC who received curative treatment. PATIENTS AND METHODS: Consecutive patients who underwent curative resection for GC at the Yokohama City University between 2005 and 2020 were selected based on their medical records. The HALP score was calculated as follows: HALP=Hemoglobin (g/l) × albumin (g/l) × lymphocytes (109/l)/platelets (109/l). RESULTS: The 3-year and 5-year overall survival (OS) rates were 88.6% and 85.8%, respectively, in patients with HALP scores of >40, and 70.3% and 57.2% in patients with HALP scores of ≤40. There were significant differences between the groups analyzed (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHemoglobinsBlood PlateletsLymphocytesHumansMaleFemaleMiddle AgedAgedPrognosisAdultBiomarkers, TumorAged, 80 and overNeoplasm StagingPlatelet CountSerum Albumin

Stichwörter der Autor:innen

Hemoglobinalbumingastric cancerlymphocyteplatelet

Substanzen

HemoglobinsBiomarkers, TumorSerum Albumin

Autor:innen und Institutionen

  • Department of Surgery, Yokohama City University, Yokohama, Japan t-aoyama@lilac.plala.or.jp.
  • Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Department of Surgery, Yokohama City University, Yokohama, Japan itarum1n1@hotmail.com.

Zitieren

APA

Aoyama, T., Maezawa, Y., Hashimoto, I., Esashi, R., Yamamoto, S., Uchiyama, M., Numata, K., Kazama, K., Tamagawa, A., Saito, A., & Yukawa, N. (2024). The Clinical Impact of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) in Gastric Cancer Patients Who Receive Curative Treatment. In Vivo. https://doi.org/10.21873/invivo.13720

Vancouver

Aoyama T, Maezawa Y, Hashimoto I, Esashi R, Yamamoto S, Uchiyama M, et al. The Clinical Impact of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) in Gastric Cancer Patients Who Receive Curative Treatment. In Vivo. 2024. doi:10.21873/invivo.13720

BibTeX
@article{Aoyama2024,
  author = {Aoyama, Toru and Maezawa, Yukio and Hashimoto, Itaru and Esashi, Ryuki and Yamamoto, Sosuke and Uchiyama, Mamoru and Numata, Koji and Kazama, Keisuke and Tamagawa, Ayako and Saito, Aya and Yukawa, Norio},
  title = {The Clinical Impact of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) in Gastric Cancer Patients Who Receive Curative Treatment},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13720}
}
Kostenlos starten →